Novartis AG - Asset Resilience Ratio
Novartis AG (NVSN) has an Asset Resilience Ratio of 0.08% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check NVSN capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Novartis AG's Asset Resilience Ratio has changed over time. See NVSN equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Novartis AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NVSN company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | MX$0.00 | 0% |
| Short-term Investments | MX$100.00 Million | 0.08% |
| Total Liquid Assets | MX$100.00 Million | 0.08% |
Asset Resilience Insights
- Limited Liquidity: Novartis AG maintains only 0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Novartis AG Industry Peers by Asset Resilience Ratio
Compare Novartis AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.48% |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096 |
Drug Manufacturers - General | 1.58% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
Annual Asset Resilience Ratio for Novartis AG (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Novartis AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.09% | MX$98.00 Million ≈ $5.64 Million |
MX$110.95 Billion ≈ $6.39 Billion |
-1.76pp |
| 2024-12-31 | 1.85% | MX$1.89 Billion ≈ $108.89 Million |
MX$102.25 Billion ≈ $5.88 Billion |
+1.28pp |
| 2023-12-31 | 0.57% | MX$569.00 Million ≈ $32.75 Million |
MX$99.94 Billion ≈ $5.75 Billion |
-9.15pp |
| 2022-12-31 | 9.72% | MX$11.41 Billion ≈ $656.82 Million |
MX$117.45 Billion ≈ $6.76 Billion |
-2.20pp |
| 2021-12-31 | 11.92% | MX$15.71 Billion ≈ $903.89 Million |
MX$131.79 Billion ≈ $7.58 Billion |
+10.47pp |
| 2020-12-31 | 1.44% | MX$1.91 Billion ≈ $109.63 Million |
MX$132.06 Billion ≈ $7.60 Billion |
+1.16pp |
| 2019-12-31 | 0.28% | MX$334.00 Million ≈ $19.22 Million |
MX$118.37 Billion ≈ $6.81 Billion |
-1.57pp |
| 2018-12-31 | 1.85% | MX$2.69 Billion ≈ $154.98 Million |
MX$145.56 Billion ≈ $8.38 Billion |
+1.38pp |
| 2017-12-31 | 0.47% | MX$625.00 Million ≈ $35.97 Million |
MX$133.08 Billion ≈ $7.66 Billion |
-0.12pp |
| 2016-12-31 | 0.59% | MX$770.00 Million ≈ $44.31 Million |
MX$130.12 Billion ≈ $7.49 Billion |
+0.11pp |
| 2015-12-31 | 0.48% | MX$630.00 Million ≈ $36.26 Million |
MX$131.56 Billion ≈ $7.57 Billion |
+0.09pp |
| 2014-12-31 | 0.39% | MX$483.00 Million ≈ $27.80 Million |
MX$125.39 Billion ≈ $7.22 Billion |
-- |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more